Trial Profile
Effect of Perioperative AntiHER-2 therapy on Early Breast Cancer Study - Biological phase.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Dec 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Trastuzumab (Primary) ; Hormones
- Indications Early breast cancer; HER2 positive breast cancer
- Focus Biomarker; Therapeutic Use
- Acronyms EPHOS-B
- 14 Feb 2022 Primary endpoint (Increase in apoptosis) has not been met according to the results published in the Clinical Cancer Research
- 14 Feb 2022 Primary endpoint (Fall in proliferation between diagnosis and surgery) has been met according to the results published in the Clinical Cancer Research
- 14 Feb 2022 Results published in the Clinical Cancer Research